Navigation Links
Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference
Date:7/13/2009

NEW YORK, July 13 /PRNewswire-FirstCall/ -- Jesup & Lamont, Inc., (Amex: JLI), a full-service boutique brokerage and investment banking firm serving retail and institutional clients, today announced the LifeTech Capital Group companies presenting at its 2009 Growth Stock & National Sales Conference to be held at the Waldorf Astoria Boca Beach Club on July 30th, 2009 in Boca Raton, Florida. In addition, former FDA Commissioner Dr. Lester M. Crawford D.V.M., Ph.D., will be the keynote speaker for the event.

"As large pharmaceutical companies continue to struggle with patent expirations, pricing pressures, R&D cuts and changes to the U.S. healthcare system, we believe smaller biotech companies represent an exciting source of value-creation for investors," says Stephen M. Dunn, Managing Director of Life Sciences Research at LifeTech Capital Group. "With the government's recent demands for comparative effectiveness of drugs, there is a corresponding increase in demand for companies with novel, breakthrough approaches. We're pleased to have such a diversified group of innovative biotech companies presenting at our conference."

Some of the companies presenting on July 30th include Peregrine Pharmaceuticals (Nasdaq: PPHM), Cytori Therapeutics (Nasdaq: CYTX), NovaBay Pharmaceuticals (Amex: NBY), Nabi Biopharmaceuticals (Nasdaq: NABI), OXiGENE Inc. (Nasdaq: OXGN), Access Pharmaceuticals (OTC Bulletin Board: ACCP), Echo Therapeutics (OTC Bulletin Board: ECTE), Raptor Pharmaceuticals (OTC Bulletin Board: RPTP), Neoprobe Corp. (OTC Bulletin Board: NEOP) and Oxygen Biotherapeutics (OTC Bulletin Board: OXBO).

Jesup's annual conference provides its clients a distinctive forum in which to visit with and hear presentations from unique growth companies in the life sciences, healthcare, aerospace and transportation industries. The conference commences with Life Science industry and investor panels on Wednesday July 29th with Company presentations on Thursday July 30th, followed by Investment Products presentations on August 1st and 2nd. Last year's conference brought together hundreds of institutional and retail investors in an intimate format.

For more information or registration to present or attend, contact your Jesup salesperson, Donald A. Wojnowski at dwojnowski@jesuplamont.com or Tammy Kraus at tkraus@jesuplamont.com. You can also register online at www.jesuplamontconferences.com.

About Jesup & Lamont, Inc.

Established in 1877, Jesup & Lamont, Inc. has an extensive history on Wall Street, with its origins encompassing such successes as providing brokerage services to Standard Oil and raising capital for the construction of Rockefeller Center. Jesup & Lamont, through its two wholly owned brokerage subsidiaries, offers full service broker-dealer and registered investment advisory services through its approximately 150 retail brokers in over 20 locations including offices in New York, San Francisco, Boston, Boca Raton, Chicago, Fort Lauderdale and Orlando. The Company's Jesup & Lamont Securities Corporation subsidiary also publishes proprietary research on several industries including Aerospace/Defense, Alternative Energy and Life Sciences/Healthcare and offers comprehensive investment banking services.

Forward-Looking Statement Disclaimer

This press release contains "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risk, uncertainties or other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, without limitation, fluctuations in the volume of transactional services provided by the Company, competition with respect to financial services commission rates, the effect of general economic and market conditions, factors affecting the securities brokerage industry as well as other risks and uncertainties detailed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to revise or update any forward-looking statement.


'/>"/>
SOURCE Jesup & Lamont, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference
2. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
3. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
4. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
5. Mirixa Corporation Announces Key New Hires
6. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
7. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
8. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
9. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
10. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
11. Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):